前沿生物(688221.SH)：拟使用不超过8亿元暂时闲置募集资金进行现金管理

Core Viewpoint - Frontier Biotech (688221.SH) announced a cash management plan for idle funds raised from its initial public offering and a simplified issuance of shares to specific targets, with a total limit not exceeding RMB 800 million, valid for 12 months from the expiration of the previous authorization period on October 14, 2025 [1] Group 1 - The total cash management limit is set at a maximum of RMB 800 million [1] - The usage period for the funds is effective for 12 months starting from the expiration date of the last authorization [1] - The funds can be used in a rolling manner within the specified limit and timeframe [1]